<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>33(3)</volume><submitter>Powers TW</submitter><pubmed_abstract>The multi-attribute method (MAM), a mass spectrometry technique for quantifying amino acid modifications at the peptide level, is becoming a prominent analytical tool in the development of biotherapeutics. The method has promise for adeno-associated virus (AAV) therapeutics, where capsid protein modifications have been directly linked to reduced transduction efficiency. Given this link, a robust and precise procedure to quantitate capsid modifications would be beneficial for implementation throughout biotherapeutic development. Herein, an AAV product was characterized, and capsid sequence liabilities were identified. A peptide map MAM method was developed to quantitate select sites of modifications and was validated according to ICH Q2(R2). Through this exercise, the method was demonstrate</pubmed_abstract><journal>Molecular therapy. Methods &amp; clinical development</journal><pagination>101560</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12410397</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development and implementation of an LC-MS-based multi-attribute method for adeno-associated virus.</pubmed_title><pmcid>PMC12410397</pmcid><pubmed_authors>Mariani S</pubmed_authors><pubmed_authors>Powers TW</pubmed_authors><pubmed_authors>Narepekha H</pubmed_authors><pubmed_authors>Sankar S</pubmed_authors><pubmed_authors>Ryan D</pubmed_authors><pubmed_authors>Lerch TF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development and implementation of an LC-MS-based multi-attribute method for adeno-associated virus.</name><description>The multi-attribute method (MAM), a mass spectrometry technique for quantifying amino acid modifications at the peptide level, is becoming a prominent analytical tool in the development of biotherapeutics. The method has promise for adeno-associated virus (AAV) therapeutics, where capsid protein modifications have been directly linked to reduced transduction efficiency. Given this link, a robust and precise procedure to quantitate capsid modifications would be beneficial for implementation throughout biotherapeutic development. Herein, an AAV product was characterized, and capsid sequence liabilities were identified. A peptide map MAM method was developed to quantitate select sites of modifications and was validated according to ICH Q2(R2). Through this exercise, the method was demonstrate</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-01T13:59:59.113Z</modification><creation>2026-04-08T13:14:05.618Z</creation></dates><accession>S-EPMC12410397</accession><cross_references><pubmed>40917693</pubmed><doi>10.1016/j.omtm.2025.101560</doi></cross_references></HashMap>